• N&PD Moderators: Skorpio

Advances in Parkinson’s Disease Treatment: The Role of Neuroscience and Pharmacology

DrJawadAhmadBajwa

Greenlighter
Joined
Jun 4, 2026
Messages
1
Location
Karachi, Pakistan
Parkinson’s disease is a progressive neurological disorder that affects movement, balance, and coordination. Over the years, significant advances in neuroscience and pharmacology have improved the way clinicians understand and manage this condition. Ongoing research continues to explore new therapies aimed at improving patient outcomes and quality of life.

Understanding the Neurological Basis of Parkinson’s Disease​

Parkinson’s disease develops primarily due to the degeneration of dopamine-producing neurons in specific regions of the brain. Dopamine is a neurotransmitter responsible for regulating movement and motor control. As dopamine levels decline, patients may experience symptoms such as tremors, rigidity, slowness of movement, and postural instability.

Neuroscientists are actively studying the mechanisms behind neuronal degeneration to identify potential targets for future treatments. Research into genetics, inflammation, and protein aggregation is providing valuable insights into disease progression.

Pharmacological Approaches to Symptom Management​

Medication remains the first line of treatment for many Parkinson’s patients. Several pharmacological options are currently available, including:

  • Levodopa-based therapies
  • Dopamine agonists
  • MAO-B inhibitors
  • COMT inhibitors
  • Anticholinergic medications
These treatments aim to increase dopamine activity or reduce symptom severity. However, long-term medication use may lead to fluctuations in symptom control, highlighting the need for individualized treatment plans.

Emerging Therapies and Future Directions​

Recent developments in neuroscience have opened the door to innovative treatment approaches. Researchers are investigating neuroprotective therapies, gene-based treatments, stem cell research, and advanced drug delivery systems. While many of these therapies remain under clinical evaluation, they represent promising opportunities for future Parkinson’s disease management.

The Importance of Multidisciplinary Care​

Successful Parkinson’s treatment often requires collaboration among neurologists, neurosurgeons, rehabilitation specialists, and pharmacology experts. Combining medication management with physical therapy, occupational therapy, and advanced interventions can help patients maintain independence and improve daily functioning.

Conclusion​

The intersection of neuroscience and pharmacology continues to drive progress in Parkinson’s disease treatment. As research advances, patients and healthcare professionals can look forward to more personalized and effective therapeutic options that address both symptoms and disease progression.
 
neurons.jpg



Parkinson's Disease Dementia

Alzheimer's Association

The brain changes caused by Parkinson’s disease begin in a region that plays a key role in movement, leading to early symptoms that include tremors and shakiness, muscle stiffness, a shuffling step, stooped posture, difficulty initiating movement and lack of facial expression. As brain changes caused by Parkinson’s gradually spread, they often begin to affect mental functions, including memory and the ability to pay attention, make sound judgments and plan the steps needed to complete a task.

The key brain changes linked to Parkinson’s disease and Parkinson’s disease dementia are abnormal microscopic deposits composed chiefly of alpha-synuclein, a protein found widely in the brain with a normal function not yet known. The deposits are called “Lewy bodies” after Frederick H. Lewy, M.D., the neurologist who discovered them while working in Dr. Alois Alzheimer’s laboratory during the early 1900s.

Lewy bodies are also found in several other brain disorders, including Lewy body dementia (LBD). Evidence suggests that Lewy body dementia, Parkinson’s disease and Parkinson’s disease dementia may be linked to the same underlying abnormalities in the brain processing of alpha-synuclein. Another complicating factor is that many people with both Lewy body dementia and Parkinson’s disease dementia also have plaques and tangles — hallmark brain changes linked to Alzheimer's disease. Sign up for our e-news to receive updates about Alzheimer’s and dementia care and research.

Prevalence

Parkinson’s disease is a fairly common neurological disorder in older adults, estimated to affect nearly 2 percent of those over age 65. The Parkinson's Foundation estimates that one million Americans have Parkinson’s disease. Recent studies following people with Parkinson’s over the entire course of their illness estimate that 50 to 80 percent of those with the disease may experience dementia.

Causes and risk factors

Certain factors at the time of Parkinson's diagnosis may increase future dementia risk, including older age, greater severity of motor symptoms and having mild cognitive impairment (MCI).

Additional risk factors may include:

- Hallucinations in a person who doesn't yet have other dementia symptoms.
- Excessive daytime sleepiness.
- Parkinson's symptom pattern known as postural instability and gait disturbance (PIGD), which includes "freezing" in mid-step, difficulty initiating movement, shuffling, problems with balance and falling.

Symptoms

Commonly reported symptoms of Parkinson's disease dementia include:

- Changes in memory, concentration and judgment.
- Trouble interpreting visual information.
- Muffled speech.
- Visual hallucinations.
- Delusions, especially paranoid ideas.
- Depression.
- Irritability and anxiety.
- Sleep disturbances, including excessive daytime drowsiness and rapid eye movement (REM) sleep disorder.

Diagnosis

There is no single test — or combination of tests — that conclusively determines that a person has Parkinson’s disease dementia. Guidelines for diagnosing Parkinson’s disease dementia and Lewy body dementia are:

The diagnosis is Parkinson’s disease dementia when a person is originally diagnosed with Parkinson’s disease based on symptoms related to movement and dementia symptoms don’t appear until a year later or more.

The diagnosis is Lewy body dementia when dementia symptoms consistent with Lewy body dementia either develop first; are present along with symptoms related to movement; or appear within one year after movement symptoms.

Outcomes

Because Parkinson’s disease and Parkinson’s disease dementia damage and destroy brain cells, both disorders worsen over time. Their speed of progression can vary widely.

Treatment

There are no treatments to slow or stop the brain cell damage caused by Parkinson’s disease dementia. Current strategies focus on improving symptoms. If your treatment plan includes medications, it’s important to work closely with your physician to identify the drugs that work best for you and the most effective doses.

Cholinesterase inhibitors — drugs that are the current mainstay for treating cognitive changes in Alzheimer's — may help Parkinson's disease dementia symptoms, including visual hallucinations, sleep disturbances and changes in thinking and behavior.

Antipsychotic drugs — a drug category sometimes prescribed for behavioral symptoms of Alzheimer’s — should be used with extreme caution because they may cause serious side effects in up to 50 percent of those with Parkinson’s disease dementia or Lewy body dementia. Side effects may include sudden changes in consciousness, impaired swallowing, acute confusion, episodes of delusions or hallucinations, or appearance or worsening of Parkinson’s symptoms.

Treating movement symptoms in those with Parkinson’s dementia can be challenging, because carbidopa-levodopa — the chief treatment for Parkinson’s movement symptoms — can sometimes aggravate hallucinations and confusion in those with Parkinson’s dementia or Lewy body dementia. Although deep brain stimulation (DBS) is currently contraindicated for Parkinson’s disease dementia, a small clinical trial conducted by University College London scientists and published in the February 2018 issue of JAMA, showed that deep brain stimulation was safe and well-tolerated in participants with Parkinson’s disease dementia.

Depression is common in individuals with Parkinson’s disease dementia and Lewy body dementia, and may be treated with a type of antidepressant called selective serotonin reuptake inhibitors (SSRIs). REM disorder may be treated with clonazepam.

https://www.alz.org/alzheimers-demen...sease-dementia
 
Top